340B Program. Home Infusion for Part B Products. Medicare Reimbursement for New Technologies. General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection.
2025 · 3rd Quarter (July 1 - Sep 30)
ASTRAZENECA PHARMACEUTICALS LP
Filed by TODD STRATEGY GROUP.
Open official filingSource-reported fields
Filing overview
- Type
- Registration - Amendment
- Posted
- Oct 15, 2025
- Income
- Not reported
- Expenses
- Not reported
- Registrant
- TODD STRATEGY GROUP
- Filing UUID
- 75ebbe08-80c9-43a1-b278-0b0866d9ec4e
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
340B Program. Home Infusion for Part B Products. Medicare Reimbursement for New Technologies. General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.